TU‐A‐BRA‐02: Incorporating PET/CT Images into 3D Ultrasound‐Guided Biopsy of the Prostate

B. Fei, D. Schuster, V. Master, P. Nieh

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: Prostate cancer is the second leading cause of cancer mortality in American men. Systematic transrectal ultrasound (TRUS)‐guided prostate biopsy is considered as the standard method for prostate cancer detection. The current biopsy technique has a significant sampling error and can miss up to 30% of cancers. As a Result, a patient may be informed of a negative biopsy Result but may in fact be harboring an occult early‐stage cancer because the current ultrasound imaging technology has difficulty to differentiate carcinoma from benign prostate tissue and because the current TRUS‐guided biopsy is blind and random. We are developing methods to combine PET/CT with three‐dimensional (3D) ultrasound images for targeted biopsy of the prostate with the aim of improving cancer detection rate. Methods: The 3D ultrasound‐guided biopsy system consists of a 3D mechanical localization system and software workstation for image segmentation, registration, and biopsy planning. For PET imaging, we use a new molecular imaging tracer called anti‐1‐amino‐3‐18F‐fluorocyclobutane‐1‐carboxylic acid ([F18]FACBC) that has shown promising results for detecting and localizing prostate cancer in our human clinical trials. In order to plan biopsy, we developed a 3D, automatic segmentation method for the prostate ultrasound images. In order to incorporate PET/CT images into ultrasound‐guided biopsy, we developed image registration methods to fuse TRUS and PET/CT images. Results: The segmentation method was tested in ten patients with a DICE overlap ratio of 92.4% ±1.1%. The registration method has been tested in phantoms. The biopsy system was tested in prostate phantoms. Three‐dimensional ultrasound images were acquired from four human patients. We are integrating the system for PET/CT directed, 3D ultrasound‐guided, targeted biopsy in human patients. Conclusions: A PET/CT image‐directed, 3D ultrasound‐guided biopsy system has been developed for the prostate. This research is supported in part by NIH grant R01CA156775 (PI: Fei), Georgia Cancer Coalition Distinguished Clinicians and Scientists Award (PI: Fei), and the Emory Molecular and Translational Imaging Center (NIH P50CA128301).

Original languageEnglish (US)
Number of pages1
JournalMedical physics
Volume39
Issue number6
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Prostate
Biopsy
Prostatic Neoplasms
Molecular Imaging
Neoplasms
Selection Bias
Organized Financing
Ultrasonography
Software
Clinical Trials
Technology
Carcinoma
Acids
Mortality

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

TU‐A‐BRA‐02 : Incorporating PET/CT Images into 3D Ultrasound‐Guided Biopsy of the Prostate. / Fei, B.; Schuster, D.; Master, V.; Nieh, P.

In: Medical physics, Vol. 39, No. 6, 06.2012.

Research output: Contribution to journalArticle

@article{e47711ad0bd844bbba0eafefe796072b,
title = "TU‐A‐BRA‐02: Incorporating PET/CT Images into 3D Ultrasound‐Guided Biopsy of the Prostate",
abstract = "Purpose: Prostate cancer is the second leading cause of cancer mortality in American men. Systematic transrectal ultrasound (TRUS)‐guided prostate biopsy is considered as the standard method for prostate cancer detection. The current biopsy technique has a significant sampling error and can miss up to 30{\%} of cancers. As a Result, a patient may be informed of a negative biopsy Result but may in fact be harboring an occult early‐stage cancer because the current ultrasound imaging technology has difficulty to differentiate carcinoma from benign prostate tissue and because the current TRUS‐guided biopsy is blind and random. We are developing methods to combine PET/CT with three‐dimensional (3D) ultrasound images for targeted biopsy of the prostate with the aim of improving cancer detection rate. Methods: The 3D ultrasound‐guided biopsy system consists of a 3D mechanical localization system and software workstation for image segmentation, registration, and biopsy planning. For PET imaging, we use a new molecular imaging tracer called anti‐1‐amino‐3‐18F‐fluorocyclobutane‐1‐carboxylic acid ([F18]FACBC) that has shown promising results for detecting and localizing prostate cancer in our human clinical trials. In order to plan biopsy, we developed a 3D, automatic segmentation method for the prostate ultrasound images. In order to incorporate PET/CT images into ultrasound‐guided biopsy, we developed image registration methods to fuse TRUS and PET/CT images. Results: The segmentation method was tested in ten patients with a DICE overlap ratio of 92.4{\%} ±1.1{\%}. The registration method has been tested in phantoms. The biopsy system was tested in prostate phantoms. Three‐dimensional ultrasound images were acquired from four human patients. We are integrating the system for PET/CT directed, 3D ultrasound‐guided, targeted biopsy in human patients. Conclusions: A PET/CT image‐directed, 3D ultrasound‐guided biopsy system has been developed for the prostate. This research is supported in part by NIH grant R01CA156775 (PI: Fei), Georgia Cancer Coalition Distinguished Clinicians and Scientists Award (PI: Fei), and the Emory Molecular and Translational Imaging Center (NIH P50CA128301).",
author = "B. Fei and D. Schuster and V. Master and P. Nieh",
year = "2012",
month = "6",
doi = "10.1118/1.4735870",
language = "English (US)",
volume = "39",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "6",

}

TY - JOUR

T1 - TU‐A‐BRA‐02

T2 - Incorporating PET/CT Images into 3D Ultrasound‐Guided Biopsy of the Prostate

AU - Fei, B.

AU - Schuster, D.

AU - Master, V.

AU - Nieh, P.

PY - 2012/6

Y1 - 2012/6

N2 - Purpose: Prostate cancer is the second leading cause of cancer mortality in American men. Systematic transrectal ultrasound (TRUS)‐guided prostate biopsy is considered as the standard method for prostate cancer detection. The current biopsy technique has a significant sampling error and can miss up to 30% of cancers. As a Result, a patient may be informed of a negative biopsy Result but may in fact be harboring an occult early‐stage cancer because the current ultrasound imaging technology has difficulty to differentiate carcinoma from benign prostate tissue and because the current TRUS‐guided biopsy is blind and random. We are developing methods to combine PET/CT with three‐dimensional (3D) ultrasound images for targeted biopsy of the prostate with the aim of improving cancer detection rate. Methods: The 3D ultrasound‐guided biopsy system consists of a 3D mechanical localization system and software workstation for image segmentation, registration, and biopsy planning. For PET imaging, we use a new molecular imaging tracer called anti‐1‐amino‐3‐18F‐fluorocyclobutane‐1‐carboxylic acid ([F18]FACBC) that has shown promising results for detecting and localizing prostate cancer in our human clinical trials. In order to plan biopsy, we developed a 3D, automatic segmentation method for the prostate ultrasound images. In order to incorporate PET/CT images into ultrasound‐guided biopsy, we developed image registration methods to fuse TRUS and PET/CT images. Results: The segmentation method was tested in ten patients with a DICE overlap ratio of 92.4% ±1.1%. The registration method has been tested in phantoms. The biopsy system was tested in prostate phantoms. Three‐dimensional ultrasound images were acquired from four human patients. We are integrating the system for PET/CT directed, 3D ultrasound‐guided, targeted biopsy in human patients. Conclusions: A PET/CT image‐directed, 3D ultrasound‐guided biopsy system has been developed for the prostate. This research is supported in part by NIH grant R01CA156775 (PI: Fei), Georgia Cancer Coalition Distinguished Clinicians and Scientists Award (PI: Fei), and the Emory Molecular and Translational Imaging Center (NIH P50CA128301).

AB - Purpose: Prostate cancer is the second leading cause of cancer mortality in American men. Systematic transrectal ultrasound (TRUS)‐guided prostate biopsy is considered as the standard method for prostate cancer detection. The current biopsy technique has a significant sampling error and can miss up to 30% of cancers. As a Result, a patient may be informed of a negative biopsy Result but may in fact be harboring an occult early‐stage cancer because the current ultrasound imaging technology has difficulty to differentiate carcinoma from benign prostate tissue and because the current TRUS‐guided biopsy is blind and random. We are developing methods to combine PET/CT with three‐dimensional (3D) ultrasound images for targeted biopsy of the prostate with the aim of improving cancer detection rate. Methods: The 3D ultrasound‐guided biopsy system consists of a 3D mechanical localization system and software workstation for image segmentation, registration, and biopsy planning. For PET imaging, we use a new molecular imaging tracer called anti‐1‐amino‐3‐18F‐fluorocyclobutane‐1‐carboxylic acid ([F18]FACBC) that has shown promising results for detecting and localizing prostate cancer in our human clinical trials. In order to plan biopsy, we developed a 3D, automatic segmentation method for the prostate ultrasound images. In order to incorporate PET/CT images into ultrasound‐guided biopsy, we developed image registration methods to fuse TRUS and PET/CT images. Results: The segmentation method was tested in ten patients with a DICE overlap ratio of 92.4% ±1.1%. The registration method has been tested in phantoms. The biopsy system was tested in prostate phantoms. Three‐dimensional ultrasound images were acquired from four human patients. We are integrating the system for PET/CT directed, 3D ultrasound‐guided, targeted biopsy in human patients. Conclusions: A PET/CT image‐directed, 3D ultrasound‐guided biopsy system has been developed for the prostate. This research is supported in part by NIH grant R01CA156775 (PI: Fei), Georgia Cancer Coalition Distinguished Clinicians and Scientists Award (PI: Fei), and the Emory Molecular and Translational Imaging Center (NIH P50CA128301).

UR - http://www.scopus.com/inward/record.url?scp=84878617334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878617334&partnerID=8YFLogxK

U2 - 10.1118/1.4735870

DO - 10.1118/1.4735870

M3 - Article

AN - SCOPUS:84878617334

VL - 39

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 6

ER -